ENDPOINTS

Vertex operations chief Stuart Arbuckle to retire

Vertex chief operating officer Stuart Arbuckle plans to retire in July, the comp...

Judge halts some NIH cuts after 22 states sue

A federal court in Massachusetts temporarily blocked the Trump administration’s ...

Merck KGaA confirms interest in acquiring cancer biotec...

German pharma company Merck KGaA confirmed that it is in talks to acquire Spring...

Eli Lilly inks $630M deal for Phase 1 MASH candidate

Eli Lilly is betting up to $630 million on an experimental MASH treatment from a...

States sue Trump administration over billions in NIH in...

Twenty-two state attorneys general sued the Trump administration on Monday in a ...

Hims’ Super Bowl ad has drawn criticism from lawmakers ...

Novo Nordisk hit back at telehealth company Hims’ controversial Super Bowl comme...

Trump’s tariff impact likely ‘minimal’ for brand-name d...

Several brand-name drugmakers believe they will withstand any drug pricing impac...

Hims’ Super Bowl ad has drawn ire from lawmakers — and ...

Novo Nordisk hit back at telehealth company Hims’ controversial Super Bowl comme...

Boehringer Ingelheim touts success in second Phase 3 lu...

Boehringer Ingelheim said its experimental treatment for a chronic lung disease ...

Roivant discontinues lung disease drug; Bio-Thera, Inta...

Plus, news about Caliway Biopharmaceuticals, Orca Bio, Alterity Therapeutics and...

Decade after $8B deal, Roche offloads InterMune to myst...

Roche's $8 billion InterMune acquisition, disclosed a decade ago, is now being h...

Pliant shares plummet as Phase 2b lung fibrosis study p...

Pliant Therapeutics has slammed the brakes on enrollment and dosing in a mid-sta...

AffyImmune’s layoffs; Henlius makes a biosimilar deal w...

Plus, news about X4 Pharmaceuticals, Viracta Therapeutics, Crown Laboratories, Q...

J&J, Intra-Cellular quickly sealed $14B deal as three o...

It took one month for Johnson & Johnson to secure its $14 billion acquisition of...

AstraZeneca takes $753M charge on abandoned complement ...

AstraZeneca has terminated all development of vemircopan, the oral factor D inhi...

AstraZeneca cuts UK funding pledge; Viking says it has ...

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential ne...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.